Search clinical trials for: JNJ-42756493: Part 3

Total 196 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Tumor or Lymphoma

United States, France, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Neoplasms | Lymphoma | Adenocarcinoma | Esophagogastric Junction

Japan
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Poland, Taiwan, China, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Poland, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus
Children's Hospital of Philadelphia
Agency for Healthcare Research and Quality (AHRQ)

Completed

Improving Otitis Media Care With Clinical Decision Support (OMHIT)

Otitis Media

United States
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
Bausch & Lomb Incorporated

Completed

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Anaphylaxis

Germany
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers

Healthy

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Kanyos Bio, Inc., a wholly-owned subsidiary of...
Pfizer

Recruiting

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Celiac Disease

United States, Australia, New Zealand
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Obesity and Diabetes Mellitus, Type 2

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
University of Vermont
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease

COPD

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Bilthoven Biologicals
Serum Institute of India Pvt. Ltd.

Completed

A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

Immune Response to Oral Polio Vaccine

Bangladesh
Trevena Inc.

Terminated

A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

Migraines

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

Healthy

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Small Cell Lung Cancer

China
University of Washington
Janssen Research & Development, LLC

Terminated

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate Carcinoma

United States
Sofia Med Hospital

Active, not recruiting

LESS TEP vs. Three Port TEP for Inguinal Hernia Repair

Inguinal Hernia

Bulgaria
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Chinese University of Hong Kong

Completed

A Randomised Controlled Trial on LESS Versus Conventional Laparoscopic Appendicectomy.

Appendicitis

China
Czech Lymphoma Study Group
Hoffmann-La Roche; Ministry of Health, Czech Republic

Completed

R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas (R-MCEB)

Diffuse Large B-Cell Lymphoma. | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma Grade III

Czech Republic
Myongji Hospital

Unknown

Transumbilical Laparoscopy-assisted Appendectomy

Appendicitis Acute

Korea, Republic of
Centro Hospitalar e Universitário de Coimbra, E...

Unknown

"Art Therapy" in Acute Psychiatry

Mood Disorders | Schizophrenia | Nurse-Patient Relations | Mental Disorder

Portugal
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: JNJ-42756493: Part 3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations